DNAPrint Genomics * Current Market Potential = $31.65 BILLION DOLLARS
DNAPrint Genomics – MARKET POTENTIAL SUMMARY - December 2006
PHARMACOGENOMICS - DIAGNOSTICS AND THERANOSTICS
CURRENT MARKET POTENTIAL = $31.65 BILLION DOLLARS
Diagnostic Products - Predictive Drug Classifier Tests
1) Ovanome - Taxol/Carboplatin - Ovarian Cancer * Market Potential - $50 Million Dollars
2) PONV – Ondansetron – Chemo-nausea * Market Potential - $500 Million Dollars
3) Statinome - Lipitor, Zocor, efficacy * Market Potential - $1 Billion Dollars
4) Melphalan/Topotecan – Multiple Myeloma * Market Potential - $50 Million Dollars
5) Acenome – Ace Inhibitors * Market. Potential - $750 Million Dollars
6) BC-LOH – Breast Cancer * Market Potential - $400 Million Dollars
7) Xeliri/Xelox – Colon Cancer * Market Potential - $200 Million Dollars
8) Diabetes - Pre-Diabetes and Diabetic Complications * Market Potential - $5 Billion Dollars
Theranostics Products – Drug and Drug Test Combinations
9) PT-201 – Opthalmic Allergies * Market Potential - $50 Million Dollars
10) PT-202 – Nasal Allergies * Market Potential - $50 Million Dollars
11) PT-301 – Atopic Dermatitis * Market Potential - $600 Million Dollars
12) PT-401 - Super EPO Anemia Drug * Market Potential - $11 Billion Dollars
12a) EPO – R103A (neuro- and cardio-protection) * Market Potential – Not stated as yet
13) PT-501 – ADHD – Methylphenidate * Market Potential - $4.6 Billion Dollars
14) PT-502 – Drug Addiction - Methylphenidate * Market Potential - $500 Million Dollars
15) PT-503 – Depression - Methylphenidate * Market Potential - $7 Billion Dollars
16) Cancer Compounds – **TI inhibitors in-licensed * Market Potential – Not stated as yet
* Current Market Potential - DNAPrint Genomics Drugs and Drug Tests = $31,650,000,000
* That's $31.65 BILLION DOLLARS....!
* Note 1 –While Forensics and Consumer Ancestry products generated over $1 million dollars in revenue last year, this Market Potential Summary only includes DNAPrint Genomics Drugs and Drug Classifiers.
* Note 2 – DNAPrint’s partner, Biofrontera’s $Multi-Million Dollar drug pipeline is not included (DNAG owns 10% of Biofrontera).
* Note 3 – Market Potential Summary also does not included licensing potential for DNAPrint’s Intellectual Property for its patents or drug licenses or potential buy-outs for Super EPO and Methylphenidate.
* Note 4 - All above information on DNAPrint's research, acquisitions, and drug products pipeline are all documented from DNAPrint’s newsletters, PR's, Analyst Reports, and SEC filings.
* Note 5 - Of course, Do Your Own DD….and make your own best informed investment decisions.
AI
